Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
Rhea-AI Summary
Aclarion (Nasdaq: ACON, ACONW), a healthcare technology company specializing in chronic low back pain location identification through biomarkers and AI algorithms, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , is scheduled for October 15, 2024.
CEO Brent Ness will represent Aclarion in a fireside chat at 2:00 PM ET. The summit will feature presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology.
Maxim senior analysts will host these sessions, providing insights into the participating companies. Interested parties can reserve their seats for the virtual event through a provided link.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ACON gained 4.81%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024
BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion’s CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15th, 2024, at 2:00 p.m. E.T.
Maxim senior analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management.
Click here to reserve your seat
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
When is Aclarion (ACON) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Aclarion (ACON) at the 2024 Maxim Healthcare Virtual Summit?
What is the focus of Aclarion's (ACON) technology?
What types of companies will be featured at the 2024 Maxim Healthcare Virtual Summit?
How can interested parties attend the 2024 Maxim Healthcare Virtual Summit featuring Aclarion (ACON)?
